Early HCV Study Outcome: PSI-7977
Pharmasset jumps on hepatitis C study results
Pharmasset Inc. on Thursday reported promising early results from a clinical trial of a hepatitis C drug candidate.
The company is testing a drug candidate called PSI-7977. In the midstage trial, a group of 63 hepatitis C patients are being treated with a combination of PSI-7977 and two older drugs, Pegasys and Copegus, or Pegasys and Copegus alone. None of the patients have received any previous treatment for the disease.
Continue reading this entire article:
Hepatitis C Ups Risk of Kidney Cancer
Experimental Polymerase Inhibitor Lowers HCV Viral Load Fast